This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Icahn School of Medicine at Mount Sinai, University of Kansas. Active years: 2020.
Company Filing History:
1 out of 535 
1 out of 571 
Years Active: 2020
Title: Ruijie Liu: Innovator in Kidney Fibrosis Treatment
Introduction
Ruijie Liu is an accomplished inventor based in New York, NY (US). She has made significant contributions to the field of medical research, particularly in the treatment of kidney fibrosis. Her innovative work has led to the development of a unique patent that addresses critical health issues.
Latest Patents
Ruijie Liu holds a patent for "Oxadiazole inhibitors of HIPK2 for treating kidney fibrosis." This patent discloses compounds that are selective inhibitors of Smad3 activation. The compounds have a specific structure where Z is an oxadiazole. These compounds are particularly useful in treating fibrotic diseases, especially renal fibrosis, and similar conditions associated with the dysregulation of the HIPK2/Smad3 signaling pathway. She has 1 patent to her name.
Career Highlights
Throughout her career, Ruijie Liu has worked with prestigious institutions such as the University of Kansas and the Icahn School of Medicine at Mount Sinai. Her research has focused on developing innovative solutions to complex medical problems, showcasing her dedication to improving patient outcomes.
Collaborations
Ruijie Liu has collaborated with notable professionals in her field, including John Cijiang He and Bhaskar C Das. These partnerships have enhanced her research and contributed to her success as an inventor.
Conclusion
Ruijie Liu's contributions to the field of kidney fibrosis treatment exemplify her innovative spirit and commitment to medical advancement. Her work continues to inspire future research and development in this critical area of healthcare.